Replies to post #53766 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

RK

Hello.

I didn't say that there was a part of your post that I didn't understand!

What I did do was correct this statement of yours:-

'But nope, no checkpoint inhibitor as of yet. Only mentioned a discussion a year ago. Nothing has become of it'

I referred you to the companies presentation of last month, where it was pointed out that two of the five conclusion points related to CI's.

So, it is still being mentioned, and the door remains open.

A question for you. What do you mean by 'they want to partner'?
Are you referring to the CI manufacturers, or are you referring to NWBO?
How do you know 'they' want to partner? Is this supposition?

Despite what you are implying with comments like 'I wouldn't hold your breath.....over a CI collaboration' I have an open mind about whether it is the right way forward.

I can see pros and cons. At the moment, I am just stating that it remains in the frame, and the fact that it was mentioned by NWBO only 2 or 3 weeks ago indicate that it remains in their thinking.

You have no idea what is going on behind the scenes. There may have been lots of partnership discussions between NWBO and BP. There may have been none. I have my own hypothesis on this.

Yes, of course it's a long road to approval, and yes two therapies will cost more than one. I think I had managed to work that out.

Whoever said it would be easy?!!!

[highwayman4life]

For now their Phase II is only being developed as a "mono-therapy" and not as a "combination therapy"

Seems to me like they are most definitely interested in Direct being a combo therapy.

NWBO's Takeaways from ASCO 2015:

We think data from the ASCO presentation are very encouraging. We are especially impressed with these positive results across diverse types of cancers in late stage patients with multiple inoperable tumors who have exhausted other treatment options, and with quite a conservative DCVax-Direct treatment regimen.

We further believe the positive data from the Phase I trial will accelerate the initiation of the planned Phase II trial of DCVax-Direct, which, in addition to the Phase III trial of DCVax-L for brain cancer, will serve as another key value driver the company.

The findings from the Phase I trial also open the door for potential combination therapy of DCVax-Direct with checkpoint inhibitors.

Thought you might find this interesting to read?

http://patents.com/us-20150273033.html

Abstract

The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.